Gut Microbiome Diversity in Adults With Inflammatory and Immune-Mediated Skin Diseases (GUMIDIC)
Studio Sulla diversità Del Microbiota Intestinale Umano in Pazienti Con Patologie Infiammatorie Cutanee
This study will examine whether the gut bacteria of adults with inflammatory or immune-mediated skin diseases differ from those of healthy adults. It will include people with atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, or bullous pemphigoid, as well as healthy controls.
Participants will provide a stool sample and complete a short food diary. The study team will analyze the bacteria in the samples and compare the results between the disease groups and healthy controls. Participants with a skin disease will be asked to provide a second stool sample and complete follow-up assessments about six months later; healthy controls will provide one sample. The study will also examine whether changes in gut bacteria are related to skin disease severity, diet, and other collected health information.
調査の概要
状態
状態
条件
条件
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Gianluca Nazzaro, MD
- 電話番号:+39 0255035200
- メール:gianluca.nazzaro@policlinico.mi.it
研究場所
-
-
-
Milan、イタリア、20122
- 募集
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
コンタクト:
- Gianluca Nazzaro, MD
- 電話番号:+39 0255035200
- メール:gianluca.nazzaro@policlinico.mi.it
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Adults aged 18 years or older with one of eight specialist-confirmed inflammatory or immune-mediated skin diseases, plus healthy adult controls without those diseases. Participants are recruited through the Dermatology service at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy.
説明
Inclusion Criteria:
- Age 18 years or older.
- Able and willing to provide informed consent.
- For patient groups: specialist-confirmed diagnosis of atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, or bullous pemphigoid.
- For healthy controls: no diagnosis of the skin diseases studied.
Exclusion Criteria:
- Unable to provide informed consent or complete the study procedures.
- Systemic antibiotic treatment within 8 weeks before recruitment or during follow-up.
- Previous intestinal surgery.
- Inflammatory bowel disease, constipation, or diarrhea.
- Long-term alcohol use.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:CASE_CONTROL
- 時間の展望:PROSPECTIVE
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
|---|
|
Atopic Dermatitis
Adults aged 18 years or older with dermatologist-confirmed atopic dermatitis. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Psoriasis
Adults aged 18 years or older with dermatologist-confirmed psoriasis. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Hidradenitis Suppurativa
Adults aged 18 years or older with dermatologist-confirmed hidradenitis suppurativa. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Vitiligo
Adults aged 18 years or older with dermatologist-confirmed vitiligo. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Acne
Adults aged 18 years or older with dermatologist-confirmed acne. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Pemphigus
Adults aged 18 years or older with dermatologist-confirmed pemphigus. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Bullous Pemphigoid
Adults aged 18 years or older with dermatologist-confirmed bullous pemphigoid. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Healthy Controls
Adults aged 18 years or older who do not have the skin diseases studied. Participants provide one stool sample and complete study assessments at baseline. |
|
Alopecia Areata
dults aged 18 years or older with dermatologist-confirmed alopecia areata. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Relative abundance of Bifidobacteriaceae in stool
時間枠:Baseline (T1)
|
Compare the relative abundance of the bacterial family Bifidobacteriaceae in stool between the combined group of adults with the eight skin diseases studied and healthy controls. Relative abundance is the number of sequences assigned to Bifidobacteriaceae divided by the total number of bacterial sequences. |
Baseline (T1)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Relative abundance of Enterobacteriaceae in stool in the combined patient group
時間枠:Baseline (T1)
|
Compare the relative abundance of Enterobacteriaceae in stool between the combined group of adults with the eight skin diseases studied and healthy controls. |
Baseline (T1)
|
|
Relative abundance of Bifidobacteriaceae by skin-disease group
時間枠:Baseline (T1)
|
Compare stool Bifidobacteriaceae relative abundance between each disease group-atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, and bullous pemphigoid-and healthy controls. |
Baseline (T1)
|
|
Relative abundance of Enterobacteriaceae by skin-disease group
時間枠:Baseline (T1)
|
Compare stool Enterobacteriaceae relative abundance between each of the eight disease groups and healthy controls. |
Baseline (T1)
|
|
Change in stool Bifidobacteriaceae and Enterobacteriaceae over time
時間枠:Baseline (T1) to 6 months (T2)
|
Assess within-person changes in the relative abundance of Bifidobacteriaceae and Enterobacteriaceae between T1 and T2 in participants with skin disease. |
Baseline (T1) to 6 months (T2)
|
|
Associations between gut bacteria and disease-related measures
時間枠:Baseline (T1) and 6 months (T2)
|
Explore associations between Bifidobacteriaceae and Enterobacteriaceae relative abundance and disease activity scores, psychological impact scores, available routine laboratory markers, dietary intake, and anthropometric measures, as specified in the protocol. |
Baseline (T1) and 6 months (T2)
|
協力者と研究者
スポンサー
スポンサー
協力者
協力者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- GUMIDIC
- 6708 (その他の識別子:Comitato Etico Territoriale Lombardia 3)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。